medigraphic.com
ISSN 2007-6517 (Print)

2014, Number 1

<< Back Next >>

Rev Latinoam Cir 2014; 4 (1)

Biochemical markers in gastroenteropancreatic neuroendocrine tumors

López EMS, Ramírez GLR, Leonher RKL, Jiménez GJA, Jópez ZJ, Medina HE

Language: Spanish
References: 34
Page: 5-9
PDF size: 229.45 Kb.


ABSTRACT

Introduction: Neuroendocrine tumors of the gastrointestinal tract represent less than 5% of all tumors of the gastrointestinal system, which are derived from the cells of the gastrointestinal diffuse endocrine system. The most are well differentiated and its diagnosis is made by light microscopy and immunohistochemistry. The objective of the study is to evaluate the importance of the use of biochemical markers for the diagnosis in patients with gastroenteropancreatic neuroendocrine tumors.
Material and methods: Case series. We selected patients diagnosed with neuroendocrine tumor located anywhere in the gastrointestinal tract and pancreas from 2009 to 2012. Data collection was obtained through medical records. We analyzed serum chromogranin A and urinary 5-hydroxy-indoleacetic.
Results: We identified 20 patients with a diagnosis of gastroenteropancreatic neuroendocrine tumor. The principal place of location was stomach with 11 cases (55%). The intensity of the chromogranin in tissue was higher in patients in stage IV and IIA of the TNM classification. The 5-hydroxy-indoleacetic acid in urine was reported in only 4 of the 20 patients. Therefore it was not possible to collect this data for statistical analysis.
Conclusion: Chromogranin A serum is a sensitive and specific marker for the presence of these tumors. Serum levels of chromogranin A can helps us to make a more accurate diagnosis in patients with suspected neuroendocrin tumors.


REFERENCES

  1. Alvarado Cabrero IA. Tumores neuroendocrinos del aparato gastrointestinal y el páncreas. Patología Revista Latinoamericana 2009;47(3):213-219.

  2. Oberg KE. The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol. 2012;24:282-293.

  3. Sanduleanu S, De Bruine A, Stridsberg M et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest. 2001;31:802-811.

  4. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumors. Endocr Relat Cancer. 2004;11:1-18.

  5. Medrano GR et al. Tumores neuroendocrinos gastroenteropancreáticos. GAMO. 2011;10(2):17-24.

  6. Wang J, Cortina G, Wu SV. Mutant neurogenin-3 in congenital malabsorptive diarrea. N Engl J Med. 2006;355:270-280.

  7. Ramage JK, Davies AHG, Ardill J et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumors. Gut. 2005;54(4):1-6.

  8. Yao JC, Hassan M, Phan A et al. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-3072.

  9. Modlin IM, Oberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:(1):61-72.

  10. Modlin IM, Kidd M, Pfragner R et al. The functional characterization of normal and neoplastic human enterochromafin cell. J Clin Endocrinol Metab. 2006;91:2340-2348.

  11. Yang HW, Kutok JL, Lee NH et al. Targeted expression of human MYCN selectively causes pancreatic neuroendocrine tumors in transgenic zebrafish. Cancer Res. 2004;64:7256-7262.

  12. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135:1469-1492.

  13. Klöppel G, Couvelard A, Perren A et al. Lineamientos de consenso de la ENETS para el estandar de atención en los tumores neuroendocrinos: hacia una estrategia estandarizada para el diagnóstico de los tumores neuroendocrinos gastroenteropancreáticos y una estratificación pronóstica. Neurondocrinology. 2009;90:162-166.

  14. Anlauf M, Perren A, Meyer CL et al. Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Gastroenterology. 2005;128(25):1187-1198.

  15. Gibril F, Reynolds JC, Doppman JL et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastasis gastrinomas. A prospective study. Ann Intern Med. 1996;125:26-34.

  16. National Comprehensive Cancer Network (NCCN Guidelines). Neuroendocrine Tumors, Version 1.2012.

  17. Solcia E, Capella C, Klöppel G. Tumours of the pancreas. Washington, DC: Armed Force Institute of Pathology; 1997: 27.

  18. O’Toole D, Grossman A, Gross D et al. ENETS Consensus guidelines for standards of care in neuroendocrine tumors: Biochemical markers. Neuroendocrinology. 2009;90:194-202.

  19. Hochwald SN, Zee S, Conlon KC et al. Prognostic factors in pancreatic endocrine neoplasms: An analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20(11):2633-2642.

  20. Heymann MF, Joubert M, Nemeth J et al. Prognostic and immunohistochemical validation of the Capella classification of pancreatic neuroendocrine tumours: an analysis of 82 sporadic cases. Histopathology. 2000;36(5):421-432.

  21. Lloyd RV. Practical markers used in the diagnosis of neuroendocrine tumors. Endocr Pathol. 2003;14:293-301.

  22. Bussolati G, Volante M, Papotti M. Classic and recent special stains used in differential diagnosis of endocrine tumors. Endocr Pathol. 2001;12:379-387.

  23. Meijer WG, Kema IP, Volmer M et al. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem. 2000;46:1588-1596.

  24. Feldman JM. Urinary serotonin in the diagnosis of carcinoid tumors. Clin Chem. 1986;32:840-844.

  25. Baudin E, Bidart JM, Rougier P et al. Screening for multiple endocrine neoplasia type I and hormonal production in apparently sporadic neuroendocrine tumors. J Clin Endocrinol Metab. 1999;84:69-75.

  26. Desftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev. 1991;12:181-187.

  27. O’Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med. 1986;314:1145-1151.

  28. Hsiao RJ, Mezger MS, O’Conner DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int. 1990;37:955-964.

  29. Strisberg M, Husebye ES. Chromogranin A and chromogranin B are sensitive circulating markers for pheochromocytoma. Eur J Endocrinol. 1997;136:67-73.

  30. Rozansky DJ, Wu H, Tang K et al. Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element. J Clin Invest. 1994;94:2357-2368.

  31. Giovanella L, La Rosa S, Ceriani L et al. Chromogranin A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings. Int J Biol Markers. 1999;14:160-166.

  32. Rozansky DJ, Wu H, Tang K, et al. Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element. J Clin Invest 1994;94:2357-2368.

  33. Giovanella L, La Rosa S, Ceriani L, et al. Chromogranin A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings. Int J Biol Markers 1999;14:160-166.

  34. O’Toole D. Current trend: endocrine tumors of the stomach, small bowel, colon and rectum. Gastroenterol Clin Biol. 2006;30:276-291.




2020     |     www.medigraphic.com